Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0009
Ciudad de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0007
Alberdi, Córdoba Province, Argentina
Local Institution - 0028
Córdoba, Córdoba Province, Argentina
Local Institution - 0010
Córdoba, Córdoba Province, Argentina
Local Institution
Buenos Aires, Distrito Federal, Argentina
Local Institution - 0025
Córdoba, Argentina
Local Institution - 0020
Prague, Czechia
Nemocnice Slany-Interna - kardiologicka ambulance
Slaný, Czechia
Local Institution - 0011
Athens, Greece
Local Institution - 0022
Athens, Greece
Start Date
November 6, 2020
Primary Completion Date
July 19, 2021
Completion Date
July 19, 2021
Last Updated
August 4, 2022
25
ACTUAL participants
BMS-986259
DRUG
Placebo
OTHER
Lead Sponsor
Bristol-Myers Squibb
NCT07372040
NCT06898515
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07199088